

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ira Sanders **Examiner:** Rodney P. Swartz
Application No.: 10/535,504 **Confirmation No.:** 9381
Filed: May 18, 2005 **Group Art Unit:** 1645
For: Treatment of Mammalian Reaction of IGE Interactions

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir/Madam:

In order to comply with the duty of disclosure prescribed under 37 C.F.R. § 1.56, transmitted herewith in connection with the above-referenced pending patent application is an Information Disclosure Statement (IDS). This IDS complies with the requirements prescribed under 37 C.F.R. § 1.98 and is being submitted pursuant to:

- 37 C.F.R. § 1.97(b)**, wherein the IDS is being offered for consideration in a:
 - national application, within three (3) months of the application filing date of the national application or before the mailing date of a first Office Action on the merits.
 - international applications, within three (3) months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 or before the mailing date of a first Office Action on the merits.
- a Request for Continued Examination (RCE) under § 1.114, before the mailing date of a first Office Action on the merits

37 C.F.R. § 1.97(c), wherein the IDS is being offered for consideration after the mailing date of a first Office Action on the merits or after the filing of an RCE under 37 C.F.R. § 1.114, but before the mailing date of a final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311 and, accordingly, is accompanied by:

the fee of \$180.00 set forth under 37 C.F.R. § 1.17(p)

or

a Statement under 37 C.F.R. § 1.97(e):

see attached Statement under 37 C.F.R. § 1.97(e).

The undersigned attorney hereby states that each item information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of this IDS.

37 C.F.R. § 1.97(d), wherein the IDS is being offered for consideration after the mailing date of a final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee and, accordingly, is accompanied by:

the fee of \$180.00 set forth under 37 C.F.R. § 1.17(p)

and

a Statement under 37 C.F.R. § 1.97(e):

see attached Statement under 37 C.F.R. § 1.97(e).

The undersigned attorney hereby states that each item information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of this IDS.

Fees & Method of Payment

There is no fee required for submission of this IDS.

The aforementioned selected fee is required for submission of this IDS.

Fee payment(s) submitted via EFS-Web.

The Commissioner is hereby authorized to charge the aforementioned selected fee to Deposit Account No. 501358.

The Commissioner is hereby authorized to charge any deficiency in fees, or credit overpayment of the same, to Deposit Account No. 501358.

Pursuant to 37 C.F.R. § 1.97(g), the filing of this IDS shall not be construed as a representation that a search has been made. Additionally, pursuant to 37 C.F.R. § 1.97(h), the filing of this IDS shall not be construed to be an admission that the information cited in this IDS is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The Examiner's attention is kindly directed to the documents identified on the enclosed/attached Form PTO/SB/08. Copies of U.S. Patents and/or Patent Application Publications, if any, are not required pursuant to 37 C.F.R. § 1.98 and, therefore, have not been provided in connection with this submission. Copies of all other references, if any, are enclosed/attached.

The Examiner's attention is further directed to the European Examination Report dated March 18, 2008 for European Application No. 03 786 972.4, which is related to the instant application. A copy of the European Examination Report is enclosed/attached, along with the references cited therein.

The references cited in this IDS should be fully considered by the U.S. Patent and Trademark Office during the examination of this application and printed on any patent that may issue thereon. Accordingly, Applicants kindly request that a copy of Forms PTO/SB/08, as considered and initialed by the Examiner, be returned with the next office communication.

An early and favorable action is respectfully requested.

Respectfully submitted,

Lowenstein Sandler PC
65 Livingston Avenue
Roseland, NJ 07068

Dated: May 18, 2010

By: s /Elizabeth Pietrowski/

Elizabeth Pietrowski
Attorney for Applicant(s)
Reg. No. 52,121